407 related articles for article (PubMed ID: 37445908)
1. Diagnostic, Prognostic, and Therapeutic Role for Angiogenesis Markers in Head and Neck Squamous Cell Carcinoma: A Narrative Review.
Alessandrini L; Astolfi L; Daloiso A; Sbaraglia M; Mondello T; Zanoletti E; Franz L; Marioni G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445908
[TBL] [Abstract][Full Text] [Related]
2. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
3. Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.
Chen L; Hu GF
Oral Oncol; 2010 Sep; 46(9):648-53. PubMed ID: 20656548
[TBL] [Abstract][Full Text] [Related]
4. Role of Vitamin D in Head and Neck Cancer-Immune Function, Anti-Tumour Effect, and Its Impact on Patient Prognosis.
Starska-Kowarska K
Nutrients; 2023 May; 15(11):. PubMed ID: 37299554
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
7. Tumor budding to investigate local invasion, metastasis, and prognosis of head and neck carcinoma: A systematic review.
Zanoletti E; Daloiso A; Nicolè L; Cazzador D; Mondello T; Franz L; Astolfi L; Marioni G
Head Neck; 2024 Mar; 46(3):651-671. PubMed ID: 38013617
[TBL] [Abstract][Full Text] [Related]
8. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
9. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapies in head and neck cancers.
Sawicki M; Szudy A; Szczyrek M; Krawczyk P; Klatka J
Otolaryngol Pol; 2012; 66(5):307-12. PubMed ID: 23036118
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
12. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
13. The role of antiangiogenic agents in the treatment of head and neck cancer.
Denaro N; Russi EG; Colantonio I; Adamo V; Merlano MC
Oncology; 2012; 83(2):108-16. PubMed ID: 22777379
[TBL] [Abstract][Full Text] [Related]
14. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
17. Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature.
Hong Q; Ding S; Xing C; Mu Z
Medicine (Baltimore); 2024 Mar; 103(9):e37387. PubMed ID: 38428879
[TBL] [Abstract][Full Text] [Related]
18. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications.
Hasina R; Whipple ME; Martin LE; Kuo WP; Ohno-Machado L; Lingen MW
Lab Invest; 2008 Apr; 88(4):342-53. PubMed ID: 18283272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
